LGMD2I/R9 research push comes as BridgeBio Pharma stock faces continued bearish pressure

Traders Union
All News
Companies
BridgeBio Pharma down 1.11% today

Highlights

BBIO remains in a bearish technical posture, trading below major moving averages and facing sustained selling pressure across timeframes.
Momentum indicators confirm weak buying interest and a lack of clear trend, with overbought signals appearing despite recent declines.
Next week's expected trading range is $66.55 to $68.28, with immediate support near $67.00 and resistance around $70.13, making further downside more likely.

Sustained seller pressure as price tests layered resistance zones

BBIO is currently trading at $66.80, sitting below the MA-20 ($67.02), MA-50 ($70.13), and MA-200 ($67.23), highlighting ongoing short-, medium-, and long-term pressure from sellers. The Ichimoku Kijun on D1 is at $67.11, which is positioned above the current price and acts as immediate resistance; near-term support is seen at the MA-20 ($67.02) and MA-200 ($67.23), while key resistance comes in at the MA-50 ($70.13) and Ichimoku Kijun ($67.11).

Bearish momentum reinforced by weak signals and persistent weekly losses

Momentum readings are weak on D1: MACD signals a strong sell and ADX indicates a lack of clear trend at 12.21. RSI is below neutral at 46.61 with Stoch RSI giving a strong sell reading, while CCI is neutral and BBP signals overbought conditions, suggesting a mix of lingering buyer pressure but waning momentum. The Awesome Oscillator is neutral and does not amplify the downward bias. BBIO is trading at $66.80, down from a previous weekly close of $67.61—reflecting a 1.20% decline across the week—and sits in the lower part of the current weekly range. Weekly volatility stands at 5.45%. The tone this week is persistently bearish with a steady slide from the recent high. In today’s session, the stock slipped 1.11%, reinforcing near-term softness.

Low upside probability as range-bound action favors further downside

Looking ahead, the expected price range for the next week is $66.55 to $68.28, which sits well above the 52-week low of $39.63 and below the 52-week high of $84.94. Based on D1 signals and W1 momentum, the probability of a meaningful price increase in the coming week is very low (less than 20%), while a decline is much more likely. The baseline scenario is for BBIO to consolidate between support at $67.02–$67.23 and resistance at $67.11–$70.13. If prices push above $67.11, a bullish move toward $68.28 could develop. A break below $66.55 would open up more negative territory, confirming the short-term bearish structure.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that BridgeBio Pharma was consolidating near resistance levels, with mixed technical signals suggesting potential for both upward breakouts and downside moves. This update provides a fresh lens on evolving market dynamics, underscoring the importance for investors to stay alert to shifts in sentiment that could tip the balance in either direction.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.